Table 7.

NHRMC evidence statement matrix.

Components	Grade	Comments
Evidence base	A-Excellent	6 out of 11 studies are level II studies. The quality of studies is good, 8 out of 11 studies score 90% and above.
Consistency	B-Good	Most studies, including 3 out of 6 studies of high-quality level II and 3 out of 4 studies of level III-3 concluded consistently. Among the 3 level II studies that reported no significant improvement, 2 studies showed an improvement trend; another 1 study has a significant baseline sexual functioning difference in comparison with the comparative group which may indicate allocation bias.
Clinical impact	C-Moderate	6 out of 11 studies including those with higher-quality reported statistical significance; however, the studies’ context varied (HSDD, SSRI-induced sexual dysfunction, etc.). The dropout rate due to side effects is around 3-12%.
Generalizability	C-Evidence is not directly generalizable to the target population but could be sensibly applied to the target population.	The included studies were conducted in different countries with subjects of 29–50-year-old women with sexual dysfunction, especially sexual desire dysfunction. However, the evidence is sensibly to be generalized for women with sexual desire disorder.
Grade of recommendation	B	Body of evidence can be trusted to guide practice in most situations.